Puviindran Bhairavy J, Wallace Shannon, Ayasoufi Katayoun, Lerner Emily, Fecci Peter E
Brain Tumor Immunotherapy Program, Duke University, Durham, North Carolina.
Department of Biomedical Engineering, Duke University, Durham, North Carolina.
Neurooncol Adv. 2025 Sep 9;7(Suppl 4):iv4-iv18. doi: 10.1093/noajnl/vdaf006. eCollection 2025 Sep.
Immunotherapies have thus far proved of limited efficacy against glioblastoma. Failures can be attributed to a host of immunosuppressive mechanisms that are either directly employed by the tumor or are instead a convenient feature of the intracranial environment. This review aims to categorize glioblastoma immune-evasive tendencies, provide an update on our understanding of etiologies, and describe newer approaches to improving therapeutic responses.
迄今为止,免疫疗法对胶质母细胞瘤的疗效有限。治疗失败可归因于一系列免疫抑制机制,这些机制要么是肿瘤直接采用的,要么是颅内环境的一个便利特征。本综述旨在对胶质母细胞瘤的免疫逃逸倾向进行分类,更新我们对病因的理解,并描述改善治疗反应的新方法。